Having trouble accessing articles? Reset your cache.

In the end, it's the royalty

Despite the positive Phase IIb asthma data reported by Theravance Inc. and partner GlaxoSmithKline plc for two of their long-acting adrenergic receptor beta 2 agonists, investors initially pushed THRX's share price down 3% on the news. A close look at the terms of the companies' 2002 deal to pool four LABAs from each company hints at the reason -

Read the full 594 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers